Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Stefania De Lorenzo"'
Autor:
Ingrid Garajová, Fabio Gelsomino, Massimiliano Salati, Francesco Leonardi, Stefania De Lorenzo, Alessandro Granito, Francesco Tovoli
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 2613-2624 (2023)
Background: Metastatic intrahepatic cholangiocarcinoma still has a dismal prognosis. The aim of our study was to investigate the prognostic role of bone metastases in patients affected by intrahepatic cholangiocarcinoma. Methods: A total of 186 metas
Externí odkaz:
https://doaj.org/article/42cc963495e44deba82040c19b4d747f
Autor:
Ingrid Garajová, Fabio Gelsomino, Massimiliano Salati, Anna Mingozzi, Marianna Peroni, Stefania De Lorenzo, Alessandro Granito, Francesco Tovoli, Francesco Leonardi
Publikováno v:
Life, Vol 13, Iss 11, p 2170 (2023)
Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option. T
Externí odkaz:
https://doaj.org/article/9cbd149114394cddba536f6d8eecaa65
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 1223-1236 (2022)
Small bowel adenocarcinoma (SBA) is a rare malignancy, with a rising incidence in recent decades, and accounts for roughly 40% of all cancers of the small bowel. The majority of SBAs arise in the duodenum and are associated with a dismal prognosis. S
Externí odkaz:
https://doaj.org/article/1de3e2102e5f4f609b98fdbb560e06bd
Autor:
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele, Franco Trevisani, Carlo Messina, Francesco Di Clemente, Sara Pini, Giuseppe Cabibbo, Alessandro Granito, Mario Domenico Rizzato, Vittorina Zagonel, Giovanni Brandi, Tiziana Pressiani, Piera Federico, Caterina Vivaldi, Irene Bergna, Claudia Campani, Fabio Piscaglia
Publikováno v:
Liver Cancer, Vol 10, Iss 4, Pp 370-379 (2021)
Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontli
Externí odkaz:
https://doaj.org/article/35465bb2f20d44ce85e4f6039cf0e079
Autor:
Giovanni Brandi, Alessandro Rizzo, Marzia Deserti, Valeria Relli, Valentina Indio, Sofia Bin, Milena Pariali, Andrea Palloni, Stefania De Lorenzo, Francesco Tovoli, Simona Tavolari
Publikováno v:
BMC Medical Genetics, Vol 21, Iss 1, Pp 1-6 (2020)
Abstract Background Polymorphisms in genes modulating xenobiotics metabolism, in particular the ABCC2 c.3972C > T single nucleotide polymorphism (SNP) at exon 28, have been suggested to increase primary liver cancer (PLC) risk. Conversely, the occurr
Externí odkaz:
https://doaj.org/article/2283919551f5421c8c3a5d5cf44daf58
Autor:
Francesco Tovoli, Pietro Guerra, Massimo Iavarone, Letizia Veronese, Matteo Renzulli, Stefania De Lorenzo, Francesca Benevento, Giovanni Brandi, Federico Stefanini, Fabio Piscaglia
Publikováno v:
Liver Cancer, Vol 9, Iss 6, Pp 744-755 (2020)
Background: Due to its poor survival, intrahepatic cholangiocarcinoma (ICC) is held to be a much more aggressive cancer than hepatocellular carcinoma (HCC). In most published series, patients were diagnosed when symptomatic. However, ICC is now incre
Externí odkaz:
https://doaj.org/article/2787c0f6745b4fef9eddc50a54657d43
Autor:
Giovanni Brandi, Angela Dalia Ricci, Alessandro Rizzo, Chiara Zanfi, Simona Tavolari, Andrea Palloni, Stefania De Lorenzo, Matteo Ravaioli, Matteo Cescon
Publikováno v:
Cancer Communications, Vol 40, Iss 9, Pp 461-464 (2020)
Externí odkaz:
https://doaj.org/article/72020fc41be84fd2b6da044ae17221fb
Autor:
Giovanni Brandi, Alessandro Rizzo, Filippo Gustavo Dall’Olio, Cristina Felicani, Giorgio Ercolani, Matteo Cescon, Giorgio Frega, Simona Tavolari, Andrea Palloni, Stefania De Lorenzo, Francesca Abbati, Veronica Mollica, Angela Dalia Ricci, Carla Serra
Publikováno v:
International Journal of Hyperthermia, Vol 37, Iss 1, Pp 479-485 (2020)
Background & aims Very few data are available in literature about the role of radiofrequency ablation (RFA) in intrahepatic cholangiocarcinoma (ICC) and previous studies are mainly case reports and case series on a very small number of patients and n
Externí odkaz:
https://doaj.org/article/6561a7b45967453abc8183dd08e4ac5a
Autor:
Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajovà, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo, Maria Aurelia Barbera
Publikováno v:
Cancer Communications, Vol 38, Iss 1, Pp 1-7 (2018)
Abstract Background Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a compl
Externí odkaz:
https://doaj.org/article/446e0629df8b4e008298881ee8bd774c
Publikováno v:
Vaccines, Vol 8, Iss 4, p 578 (2020)
Immune checkpoint inhibitors (ICIs) are beginning to show promise in the clinical management of hepatocellular carcinoma (HCC). Most recently, the anti-programmed death protein-1 (PD-1) agent atezolizumab combined with bevacizumab demonstrated superi
Externí odkaz:
https://doaj.org/article/30c8d7f0482147e998baee492d9f24ca